Tag: inflammation

Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors

Medical Opinion Concludes that Beyond Oil has Potential to Reduce Gastrointestinal Cancer Risk Among Consumers of Fried Foods and Food Service Workers

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.

Jacksonville, FL, June 17, 2025 (GLOBE NEWSWIRE) -- Weight loss is a humongous challenge that many people struggle with. Lack of motivation to continue a healthy lifestyle, diet, exercise, and hormonal imbalance, pave the path for weight loss supplements for an obese person. SlimJaro emerged as a trending fruitful and healthy weight loss product. It offers the perfect blend of natural ingredients, providing sustainable, long-lasting, and safe results.

WEST PALM BEACH, FLORIDA, June 17, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its critical access hospital, Big South Fork Medical Center located in Oneida, Tennessee, has commenced offering wound care services to patients both on an inpatient and outpatient basis. The hospital has experienced a growing demand for wound care services in its market service area, particularly for diabetic patients who have wounds often characterized by excessive inflammation and reduced angiogenesis and have a higher risk for postoperative wound healing complications.

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.